
Claims:

1. A compound of Formula 1,



1

or a pharmaceutically acceptable salt thereof.

2. The compound or pharmaceutically acceptable salt according to claim 1, which has an enantiomeric purity:

(a) equal to or greater than 20% enantiomeric excess (ee); and/or

(b) equal to or greater than 40% ee; and/or

(c) equal to or greater than 60% ee; and/or

(d) equal to or greater than 80% ee; and/or

(e) equal to or greater than 90% ee; and/or

(f) equal to or greater than 98% ee; and/or

(g) equal to or greater than 99% ee; and/or

(h) equal to 100% ee.

3. The compound or pharmaceutically acceptable salt according to claim 1 or 2, wherein the compound is not in salt form.

4. A pharmaceutical composition comprising:

(a) the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3; and

(b) a pharmaceutically acceptable excipient.

5. A combination comprising the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, or the pharmaceutical composition according to claim 4, and at least one additional pharmacologically active agent.

6. The combination according to claim 5, wherein the compound or pharmaceutically acceptable salt thereof, or pharmaceutical composition and the at least one additional pharmacologically active agent is suitable to be administered simultaneously, sequentially or separately.

7. A kit comprising the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, or the pharmaceutical composition according to claim 4, and a pharmaceutical composition comprising at least one additional pharmacologically active agent.

8. The combination according to claim 5 or 6, or the kit according to claim 7, wherein the additional pharmacologically active agent is:

(a) selected from the group consisting of: levodopa, a DOPA decarboxylase inhibitor, a dopamine agonist, an anticholinergic, a B-selective monoamine oxidase inhibitor, and a catechol *O*-methyl transferase inhibitor; and/or

(b) amantadine; and/or

(c) levodopa in combination with a DOPA decarboxylase inhibitor; and/or

(d) selected from the group consisting of: carbidopa; benserazide; methyldopa; α-difluoromethyl-DOPA; 3',4',5,7-tetrahydroxy-8-methoxyisoflavone; apomorphine hydrochloride; bromocriptine; rotigotine; pramipexole; ropinirole; trihexyphenidyl; benztropine mesylate; safinamide; selegiline; rasagiline; entacapone; and tolcapone; and/or

(e) selected from the group consisting of: beta-secretase inhibitors, gamma-secretase inhibitors, HMG-CoA reductase inhibitors, and nonsteroidal anti-inflammatory drugs (NSAIDs); and/or

(f) selected from the group consisting of: apazone, aspirin, celecoxib, diclofenac (with and without misoprostol), diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate sodium, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, choline and magnesium salicylates, salsalate, and sulindac; and/or

(g) selected from the group consisting of: donepezil, rivastigmine, memantine, and galantamine; and/or

(h) selected from the group consisting of: sedatives, hypnotics, anxiolytics, antipsychotics, and tranquilizers; and/or

(i) selected from the group consisting of: amitriptyline, amoxapine, aripiprazole, asenapine, bupropion, chlordiazepoxide, citalopram, chlorpromazine, clozapine, desipramine, desvenlafaxine, doxepin, duloxetine, escitalopram, fluoxetine, fluphenazine, haloperidol, iloperidone, imipramine, isocarboxazid, lamotrigine, levomilnacipran, lurasidone, mirtazapine, nefazodone, nortriptyline, olanzapine, paliperidone, paroxetine, perphenazine, phenelzine, protriptyline, quetiapine, risperidone, safinamide, selegiline, sertraline, tranylcypromine, trazodone, trimipramine, venlafaxine, vilazodone, vortioxetine, and ziprasidone; and/or

(j) selected from the group consisting of: alprazolam, chlordiazepoxide, clobazepam, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, prazepam, quazepam, temazepam, and triazolam, hydroxyzine, eszopiclone, zaleplon, zolpidem, zopiclone, and buspirone; and/or

(k) selected from the group consisting of: acetazolamide, carbamazepine, clobazam, clonazepam, eslicarbazepine acetate, ethosuximide, gabapentin, lacosamide, lamotrigine, levetiracetam, nitrazepam, oxcarbazepine, perampanel, piracetam, phenobarbital, phenytoin, pregabalin, primidone, retigabine, rufinamide, sodium valproate, stiripentol, tiagabine, topiramate, vigabatrin, and zonisamide.

9. A dosage form comprising the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, and a pharmaceutically acceptable excipient, wherein the dosage form is adapted for oral administration of the compound or pharmaceutically acceptable salt thereof at a dose within a range selected from the group consisting of: 30 mg/kg to 40 mg/kg, 35 mg/kg to 45 mg/kg, 40 mg/kg to 50 mg/kg, 45 mg/kg to 55 mg/kg, 50 mg/kg to 60 mg/kg, 55 mg/kg to 65 mg/kg, and 60 mg/kg to 70 mg/kg.

10. The dosage form according to claim 9, wherein the dose is:

(a) within the range of 40 mg/kg to 60 mg/kg; and/or

(b) about 50 mg/kg; and/or

(c) selected from the group consisting of: 35 mg/kg, 36 mg/kg, 37 mg/kg, 38 mg/kg, 39 mg/kg, 40 mg/kg, 41 mg/kg, 42 mg/kg, 43 mg/kg, 44 mg/kg, 45 mg/kg, 46 mg/kg, 47 mg/kg, 48 mg/kg, 49 mg/kg, 50 mg/kg, 51 mg/kg, 52 mg/kg, 53 mg/kg, 54 mg/kg, 55 mg/kg, 56 mg/kg, 57 mg/kg, 58 mg/kg, 59 mg/kg, 60 mg/kg, 61 mg/kg, 62 mg/kg, 63 mg/kg, 64 mg/kg, and 65 mg/kg.

11. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1 to 3, the pharmaceutical composition according to claim 4, the combination according to claim 5, 6 or 8, the kit according to claim 7 or 8, or the dosage form according to claim 9 or 10, in the manufacture of a medicament for treating a disease, disorder or condition associated with GPR6.

12. The use according to claim 11, wherein the disease, disorder or condition is selected from the group consisting of: Parkinson's disease, levodopa-induced dyskinesias, Huntington's disease, drug addiction, eating disorders, cognitive disorders, schizophrenia, bipolar disorder, epilepsy, Alzheimer's disease, anxiety, and depression.

13. The use according to claim 11, wherein the disease, disorder or condition is Parkinson's disease.

14. The use according to claim 13, wherein the treatment improves the motoric symptoms of the subject.

15. The use according to claim 11, wherein the disease, disorder or condition is a non-motor clinical manifestation of Parkinson's disease.

16. The use according to any one of claims 11 to 15, wherein the compound or pharmaceutically acceptable salt thereof is to be administered or formulated for administration at a dose between 40 mg/kg and 60 mg/kg.

17. The use according to any one of claims 11 to 15, wherein the compound or pharmaceutically acceptable salt thereof is to be administered or formulated for administration at a dose within a range selected from the group consisting of 30 mg/kg to 40 mg/kg, 35 mg/kg to 45 mg/kg, 40 mg/kg to 50 mg/kg, 45 mg/kg to 55 mg/kg, 50 mg/kg to 60 mg/kg, 55 mg/kg to 65 mg/kg, and 60 mg/kg to 70 mg/kg.

18. The use according to any one of claims 11 to 15, wherein the compound or

pharmaceutically acceptable salt thereof is to be administered or formulated for administration at a dose of about 50 mg/kg.

19. The use according to any one of claims 11 to 18, wherein the compound or pharmaceutically acceptable salt thereof, pharmaceutical composition, combination, kit, or dosage form is to be orally administered or formulated for oral administration.